Dow Jones
38.571,03 -115,29 (-0,30%) Nasdaq
16.828,67 +93,65 (+0,56%) Nikkei 225
38.670,37 -252,66 (-0,65%) EUR/USD
1,0913 +0,0007 (+0,07%) Bitcoin EUR
63.225,24 +710,50 (+1,14%) CMC Crypto 200
1.444,52 -23,41 (-1,60%)
IN8bio, Inc. (INAB)
Dopo ore:
| Chiusura precedente | 1,1900 |
| Aperto | 1,2300 |
| Denaro | 1,0400 x 100 |
| Domanda | 1,1000 x 100 |
| Min-Max giorno | 1,0424 - 1,2300 |
| Intervallo di 52 settimane | 0,6500 - 3,0500 |
| Volume | |
| Media Volume | 333.857 |
| Capitalizzazione | 48,095M |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,9000 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 7,60 |
GlobeNewswireIN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
Enrollment is now open in the company-sponsored Phase 2 clinical trial of INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM). Enrollment completed in the dose escalation phase of the investigator-sponsored trial of INB-100 in leukemia patients with a clinical update expected at the American Society of Hematology (ASH) Annual Meeting. R&D Day held today, October 12, 2023 (9:00am-12:00pm EDT). Register online for webcast here. NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- IN8bio,
- GlobeNewswire
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced two poster presentations reporting positive data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place November 1-5, 2023, in San Diego, CA. The presentations will showcase biological correlative data from the ongoing Phase 1 clinical trial of INB-200, targeting newly diagno
- GlobeNewswire
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
Management presentations will highlight IN8bio’s clinical and scientific programs, including upcoming data releases at several upcoming fall medical meetingsFeatured presentations by clinical thought leaders including Leo Luznik, M.D., Professor of Oncology at Johns Hopkins Medicine and Michael Bishop, M.D., Director of the David and Etta Jonas Center for Cellular Therapy at The University of Chicago NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-sta
